---
title: "Protagonist Therapeutics (PTGX) Receives a Buy from Wedbush"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295398294.md"
description: "Wedbush analyst Yun Zhong assigned a Buy rating to Protagonist Therapeutics (PTGX) with a $173 price target. This aligns with the stock's Strong Buy consensus and an average price target of $158.10."
datetime: "2026-08-10T11:16:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295398294.md)
  - [en](https://longbridge.com/en/news/295398294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295398294.md)
generator: "portal-rs"
---

# Protagonist Therapeutics (PTGX) Receives a Buy from Wedbush

Wedbush analyst Yun Zhong assigned a Buy rating to Protagonist Therapeutics today and set a price target of $173.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Opus Genetics, and Voyager Therapeutics. According to TipRanks, Zhong has an average return of -6.7% and a 41.69% success rate on recommended stocks. 

Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $158.10.

### Related Stocks

- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [MNKD.US](https://longbridge.com/en/quote/MNKD.US.md)
- [VYGR.US](https://longbridge.com/en/quote/VYGR.US.md)

## Related News & Research

- [How Investors Are Reacting To Protagonist Therapeutics (PTGX) Turning ICOTYDE Milestones Into Q2 Profit](https://longbridge.com/en/news/298232620.md)
- [Protagonist Therapeutics CEO Dinesh V. Patel disposes of common shares worth USD 18.25 million](https://longbridge.com/en/news/298662260.md)
- [Protagonist Therapeutics Announces $300 Million Share Repurchase Program | PTGX Stock News](https://longbridge.com/en/news/298360476.md)
- [58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC](https://longbridge.com/en/news/297400133.md)
- [Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 | PTGX Stock News](https://longbridge.com/en/news/297775249.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**